viewAgile Therapeutics

FDA accepts Agile Therapeutics's new drug application for contraceptive patch Twirla

The regulator assigns November 16, 2019 as the goal date to communicate their decision on approval

Agile Therapeutics' Twirla
Twirla is designed to be applied once weekly for three weeks, followed by a week without the patch

Agile Therapeutics Inc (NASDAQ:AGRX) stock shot up Wednesday after it announced that the US Food and Drug Administration has accepted for review its new drug application resubmission for Twirla, a promising investigational low-dose combined hormonal contraceptive patch.

Investors hailed the news sending shares in Agile Therapeutics up nearly 8.5% to $1.53 before the opening bell.

The Princeton, New Jersey-based women’s health-care company had originally submitted an application for FDA approval in June 2017.

The NDA resubmission was submitted on May 16, and Agile said it is intended to satisfy a complete response letter the regulator sent Agile, questioning the manufacturing process at a third-party facility and the adhesion properties of it proprietary patch technology called Skinfusion, among other issues.

READ: Agile Therapeutics resubmits new drug application for Twirla contraceptive patch to FDA

In a statement, Agile said its resubmitted application also includes the comprehensive results from a comparative wear study (Twirla vs. Xulane, produced by Mylan Pharmaceuticals Inc (NASDAQ:MYL) that was requested by the FDA to address patch adhesion questions, information on the company’s manufacturing process with partner Corium Inc, and other analyses.

The company had earlier expected the FDA to acknowledge its submission as a complete response in about 30 days.

The regulator has now acknowledged the resubmission as a “complete, class 2 response to the CRL” and has assigned November 16, 2019 as the Prescription Drug User Fee Act (PDUFA) goal date. That date actually is when the FDA could approve the patch. 

The PDUFA is a law passed by the US Congress which allows the FDA to collect fees from drug manufacturers to fund the new drug approval process.

“The acceptance of our NDA for review represents a significant milestone for Agile," Agile Therapeutics CEO Al Altomari said in a statement. “Now that the FDA has acknowledged our NDA resubmission as a complete response to the CRL, we look forward to continuing to work with the FDA during their review.”

Twirla, also known as AG200-15, is designed to be applied once weekly for three weeks, followed by a week without a patch. The company has eight patents covering Twirla. Its active ingredients are ethinyl estradiol, a synthetic estrogen, and levonorgestrel, a progestin.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 


Quick facts: Agile Therapeutics

Price: 2.83 USD

Market: NASDAQ
Market Cap: $246.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Agile Therapeutics named herein, including the promotion by the Company of Agile Therapeutics in any Content on the Site, the Company receives...


2 min read